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ABSTRACT OF DISSERTAION 
LYCOPENE AND ITS POTENTIAL NUTRITIONAL ROLE FOR PATIENTS WITH HEART FAILURE 
 
 
Lycopene is a antioxidant found in natural and processed foods. The connection 
between antioxidants and heart disease has been explored in several observational studies1-4, 
yet very few investigators have examined the impact of dietary antioxidants in patient with 
advanced heart disease such as heart failure (HF). A novel strategy for preventing or delaying 
the complications of HF related to inflammation and oxidative stress may be to increase dietary 
lycopene. 
The purpose of this dissertation was to test the impact of dietary intervention consisting 
of lycopene (V8® juice) on biomarkers of inflammation and oxidative stress in patients with HF; 
Prior to testing the dietary intervention, preliminary work was conducted: 1) a review of the 
literature on dietary lycopene interventions in patients with HF and 2) a longitudinal study to 
examine whether lycopene and sodium intake interact to produce an effect on event-free 
survival in patients with HF. 
Forty patients with HF were randomly assigned to one of two treatment groups 
(intervention and usual care).  The intervention group received 24 mg of lycopene by drinking 
11.5 ounces of V8®100% vegetable juice daily for 30 days.  The usual care group continued their 
usual diet.  Serum levels of uric acid and C-reactive protein were obtained to determine the 
impact of the lycopene dietary intervention. Patients in the intervention group had higher 
levels of plasma lycopene after one month drinking V8® juice.  We also found a significant 
decrease in plasma CRP levels among women in the intervention group, while there was no 
change in CRP levels among men in the intervention group.  
 
 
 This dissertation has provided insight about lycopene as a potential nutritional 
intervention for patients with HF, aimed at reducing inflammation and oxidative stress. This 
dietary intervention is practical, easy to replicate, cost effective and is safe for patients with HF. 
Additional research is needed to determine the effects of long-term outcomes of dietary 
antioxidants in patients with HF. 
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CHAPTER ONE 
Introduction 
Heart failure (HF) is a growing concern for healthcare providers due to upward spiraling 
rates of rehospitalizations.5-7  HF places a tremendous economic burden on our healthcare 
system with the cost of hospitalizations exceeding 39.2 billons for 2010.8 HF has affected nearly 
5.8 million patients in the US, with the American Heart Association (AHA) estimating 670,000 
new cases will develop each year.9  Heart failure is primarily a condition of the elderly, as the 
incidence of HF approaches 10 cases per 1000 in those over the age of 65.9 10  This condition is 
responsible for 900,000 hospitalizations annually, more than for any other medical cause 
among the elderly.8  
Nutrition could play an important role in the prevention and treatment of HF.11  HF is a 
multisystem disorder in which systemic inflammation is a predominant process in the 
pathophysiology of HF. Inflammation is a potential target for nutrition therapy.12 However, 
current evidence-based guidelines provide very little in the way of recommendations for the 
nutritional management of patients with HF.13, 14 The reason for the lack of guideline 
recommendations related to nutrition is the limited amount of research in this area.   
Certain foods have components that potentially could attenuate inflammatory 
processes by providing exogenous antioxidant sources to supplement the endogenous 
antioxidant defense system. Oxidative stress occurs when the endogenous antioxidant defense 
system is overwhelmed by reactive oxygen species (ROS).15, 16  Reactive oxygen species are 
formed intracellularly during mitochondrial electron transport and cause damage to the 
myocardium.17-19  The response to myocardial damage is activation of the inflammatory 
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process, which begins with endothelial secretion of chemotatic molecules and can lead to 
cardiac dysfunction, cardiac apoptosis and/or necrosis. 18, 19 Thus of particular nutritional 
interest is the antioxidant effect of certain bioactive food compounds that potentially reduce 
the inflammation process in HF.  
There is abundant evidence that dietary patterns characterized by high intake of fruits 
and vegetables are associated with a lower risk of obesity, hypertension, diabetes, cancers, 
stroke and coronary heart disease, all of which have some degree of systemic inflammation 
implicated in their pathophysiology.20-25 The mechanism by which fruits and vegetables reduce 
cardiovascular disease risk has not been defined clearly. A plausible explanation may be the 
antioxidants present in all fruits and vegetables.26 The bioactivity of antioxidants may account 
for the cardioprotective benefit seen when fruits and vegetables are consumed in large 
amounts. 
Antioxidants are biochemical nutrients found in foods that can prevent or slow the 
oxidative damage to the human body, enhance immune defense and lower the risk of 
inflammation.27-30  Antioxidants are found abundantly in fruits and vegetables, as well as in 
other foods including nuts, grains, and some meats, poultry, and fish. Antioxidants exist in 
exogenous and endogenous forms. 
Exogenous antioxidants must be obtained through the diet.  The most common 
exogenous antioxidants are micronutrients like vitamin A, C and E, and phytochemicals such as 
flavonoids and carotenoids27 ( see Table 1-1 for a glossary of terms). Endogenous antioxidants 
occur naturally in the body. The endogenous antioxidant defense system includes superoxide 
dismutase (SOD), glutathione peroxidase (GPx), and catalase(CAT)31 Both forms of antioxidants 
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protect cells from the oxidative stress caused by unstable molecules known as free radicals. 
Reactive oxygen species are a type of free radical.28, 30, 32   
Free radicals are the natural by-products of normal cell processes. Free radicals are 
molecules with incomplete electron shells that make them more chemically reactive than those 
with complete electron shells.31 Antioxidants neutralize free radicals by donating one of their 
own electrons, ending the electron-"stealing" reaction.30 Despite donating an electron, 
antioxidants remain stable and don’t become free radicals themselves.  By reducing the 
negative consequences of oxidative stress, antioxidants prevent cell and tissue damage that can 
lead to disease.17, 30 Under homeostatic conditions, there is balance between oxidative activities 
and intracellular levels of antioxidants and this balance is vital for the survival of organisms and 
health. 30, 31, 33   The disruption of this balance is thought to be the genesis of a multitude of 
diseases. 31, 33 
Lycopene is a naturally occurring antioxidant and a micronutrient with important health 
benefits.  Lycopene exhibits antioxidant action by (1) exerting its strong affinity for singlet 
oxygen quenching, (2) protecting cells from lipid peroxidation and (3) enhancing cellular gap 
junction communication.34-37  Lycopene may actually stimulate the endogenous enzymatic 
antioxidant system.34, 38  
Tomatoes and tomato products are a major source of lycopene in the diet. 
Approximately 80% of the lycopene consumed in the U. S. comes from processed tomato 
products.39  Tomatoes and tomato products are considered healthy as they are cholesterol free, 
low in calories and fat, good sources of vitamins A, C & E, as well as potassium and lycopene.  A 
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diet rich in lycopene-rich food products may have potential health benefits for individuals with 
a high oxidative stress load.  
The past decade has seen a number of improvements in treatment options for patients 
with HF, specifically in pharmacologic regimens. Researchers have gained a better 
understanding of the pathophysiology of the condition, but more is needed. Researchers and 
clinicians are now looking for less demanding treatment options for the patient with HF. As it 
stands, patients with HF must become expert self care clinicians to manage their condition on a 
daily basis. Treatment strategies that are easily adapted, low cost, without side effects, and can 
be part of a daily routine without intensive external monitoring are needed. Therefore this 
dissertation is centered on the research question “Can lycopene, as a potent antioxidant, found 
naturally and abundantly in fruits and vegetables, be used as a dietary intervention in patients 
with HF to reduce inflammation and improve outcomes?” 
In chapter two of this dissertation, the results of a critical review of the literature 
related to antioxidant use in HF are presented. This review began as a broad investigation into 
lycopene as an antioxidant. The review then narrowed to focus on research studies using 
lycopene as a dietary intervention in HF.  Lastly, the review focused specifically on studies in 
which patients with HF were enrolled as the sample population to test dietary interventions 
with lycopene. 
In chapter three of this dissertation, the results of a study designed to determine 
whether higher intake of lycopene would be associated with better event free survival in 
patients with HF, independent of sodium content are presented. This was a longitudinal, 
prospective study of 212 patients with HF. Food diaries were kept by patients for four days. Diet 
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nutrient analysis was performed using Nutrition Data System Software™. Patients were 
grouped by the median split of lycopene level of 2471 mcg/day and stratified by daily sodium 
intake levels above and below 3 grams. Patients were followed for up to 3 years to collect data 
on HF hospitalization and cardiac mortality. Cox proportional hazard regression was used to 
compare differences in cardiac event-free survival between higher and lower lycopene intake 
groups within each stratum of sodium intake level. Lycopene intake above 2471 mcg/day was 
associated with longer cardiac event-free survival compared with lower lycopene intake after 
controlling for age, gender, HF etiology, body mass index, NYHA functional class, LVEF, and total 
comorbidity score (p = .003). The worst cardiac event-free survival was observed in the low 
lycopene intake group regardless of sodium intake level.  
In chapter four, results are presented from a randomized, controlled pilot study. This 
was a study conducted to determine the feasibility of a lycopene intervention in patients with 
HF, assessing for the impact of lycopene intake on biomarkers of inflammation and oxidative 
stress. Forty patients with HF (age 66 ± 10, 43% female) were randomized to either a usual care 
control group or a 30 day dietary intervention of daily lycopene intake. Patients randomized to 
the lycopene group consumed an 11.5 ounce can of V8® low-sodium vegetable juice once a day 
for 30 days. This 100% vegetable juice provided 24mg of lycopene. Serum samples of c-reactive 
protein (CRP), uric acid and b-type natriuretic peptide (BNP) were obtained pre and post 
intervention. Dietary intake was established with 4- randomly placed phone calls to collect 24-
hour dietary recalls per patient over the 30 days. We used repeated measures ANOVA to test 
the impact of the intervention and controlled for disease severity using BNP as a surrogate 
measure. 
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Chapter five includes a summary and concluding remarks based on all the chapters. 
Recommendations for practice and future research are outlined. 
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CHAPTER TWO 
Lycopene: A Critical Review of the Literature 
Introduction 
 The purpose of this paper is to critically analyze the literature on the impact of dietary 
lycopene interventions on inflammation and oxidative stress in patients with HF. Research in 
the past two decades has found a strong link of the inflammatory response and oxidative stress 
with disease progression in HF12, 40-42, yet there is little research about non-drug interventions 
to address this problem. 
 HF has an inflammatory component that is manifested in the following features: 1) 
reduced myocardial contractility; 2) left-ventricular dysfunction; 3) reduced cardiac index; and 
4) endothelial dysfunction. There are currently three recognized pathways for inflammatory 
activation in HF: 1) direct antigenic stimulation, as is the case of a virus or bacteria infecting the 
myocardium; 2) activation secondary to cardiac injury such that the myocardium renders 
autoimmune type antigens capable of generating an inflammatory response against the heart; 
and 3) activation as a result of cytokine release by the cardiac cells, in response to 
hemodynamic stress on the vasculature or the cellular level of heart tissue42.  
Inflammation in HF 
Specific serum biomarkers of inflammatory status in HF have been identified and include 
C-reactive protein (CRP).  This biomarker has been studied extensively and has a strong 
association with HF disease severity40, 43-46.  A basic understanding of the underlying 
mechanisms of inflammation, oxidative stress and the antioxidant defense system against a 
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permanent threat to myocardial cells is important to understanding why lycopene might be a 
potential intervention to reduce inflammation in HF.   
Oxidation is a normal consequence of cellular metabolism.  Oxidative stress is an 
abnormal imbalance between the antioxidant system and the byproducts of oxidation. Free 
radicals are the result of oxidation, are potentially harmful, but are usually checked by the 
antioxidant system. Free radicals are connected with the development of diseases such as 
cancer, diabetes, infections, cardiovascular disease and also are thought to play a role in the 
aging process 40. The regulation of oxidation is vital for maintenance of cellular homeostasis, 
however conditions of excess free radical production (oxidative stress) result in  cell damage, 
frequently leading to cell and tissue dysfunction and ultimately to conditions such as HF47-49.  In 
a study by White et al., patients with worsening HF and with a mean ejection fraction (EF) of 
23% had evidence of significantly higher levels of biomarkers of oxidative stress and 
inflammation when compared to age-matched controls50.   
Oxidative stress in HF 
To better understand oxidative stress, a review of the cellular components involved is 
important. Mitochondria are considered to be the main cellular source of reactive oxygen 
species (ROS; i.e., molecules that result from oxidation) during homeostasis49. Free radicals are 
inherently unstable by virtue of their single unpaired electron, thus tending to be highly 
reactive and transient. When free radicals come into contact with oxygen, a single electron is 
paired and the result is superoxide radical anion47, 49.  Superoxide radical anion is considered to 
be the starter radical from which all other oxygen radicals are derived. Superoxide anion can act 
as both an oxidant and a reductant, depending on the environmental pH and the substrate with 
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which it reacts51. Superoxide radicals are rapidly converted to hydrogen peroxide, and further 
catalyzed by enzymes to a hydroxyl radical, which is the most potent oxidant in aerobic 
metabolism51. Minimal cellular damage is achieved when the response includes endogenous 
and exogenous interacting systems of antioxidant compounds, antioxidants enzymes and repair 
enzymes. 
Oxidative stress results from increased exposure to oxidants or from decreased 
protection against oxidants, both of which may occur simultaneously, thus creating an 
imbalance51. The first level of response to oxidative stress is the antioxidant defense and repair 
system that minimizes the damage that naturally occurs in the presence of ROS52.  Antioxidant 
compounds are sacrificed to oxidants in order to directly protect more important cellular 
components. Antioxidants have a variety of chemical structures and are either water-soluble or 
fat-soluble. Antioxidants are either synthesized in the body (endogenous) or consumed in the 
diet (exogenous).  Examples of endogenous antioxidants include uric acid, coenzyme Q, lipoic 
acid, and some steroid hormones such as estrogens. Dietary antioxidants include vitamins C, E, 
carotenoids, and phenolic compounds.  
This paper focuses on lycopene as a dietary antioxidant. Lycopene is the most 
predominant carotenoid in human plasma. Lycopene is  a carotenoid found naturally in plant 
sources and has a chemical structure with 11 linearly arranged conjugated double bonds and 2 
non-conjugated double bonds53.  Because of the high number of conjugated double bonds, 
lycopene is considered one of the most potent antioxidants due to its singlet oxygen-quenching 
ability 19, 37.   
Lycopene 
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More than 600 carotenoids have been discovered and share a common structural 
feature, such as a polyisoprenoid structure and conjugated double bonds 53. The chemical 
structure of carotenoids is a key determinant of the physical property, chemical reactivity and 
biologic function observed36. Carotenoids are strongly influenced by other molecules in the 
environment, particularly proteins and lipids. The unique structure and combination of 
carotenoids may influence the bioavailability, absorption, circulation and distribution of 
lycopene in tissues37 36, 53. Carotenoids are natural pigments synthesized by plants and 
microorganisms37. The majority of carotenoids, including lycopene, are without vitamin A 
activity. The interest in lycopene has grown recently due to studies that have suggested a role 
in human health and disease34, 54.  
More than 80% of lycopene consumed in the United States is from tomatoes and 
tomato products 54.  The primary sources for lycopene in the diet are spaghetti/pasta sauce, 
ketchup, salsa, tomato soup, canned tomatoes, raw tomatoes, tomato sauce, tomato paste, 
vegetable juice cocktail, and watermelon39.  Other fruits such as apricots, guava, papaya and 
pink grapefruit also contribute lycopene to the diet. Lycopene concentration varies as a result 
of the color and type of tomato. Some deep red varieties contain 50mg per 100 grams of raw 
material (about the size of one medium tomato), while yellow varieties contain 5mg/100 grams 
(100 grams = 3.5 ounces)39, 54.  Lycopene has varied bioavailability and has tissue specific 
distribution related to its lipophilic nature; both of these characteristics are important in the 
role of an antioxidant 39.  
Bioavailability of Lycopene 
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Many factors can influence the bioavailability of lycopene, such as the food matrix 
containing the lycopene, the absorption rate of the stomach and the co-ingestion of fat as a 
delivery medium 37.  Thermal processing such as cooking with heat causes a disruption of the 
chemical structure of lycopene and enhances bioavailability55, 56. The improved bioavailability of 
lycopene from processed foods has also been attributed to its release from the ruptured plant 
cells during mechanical processing (grinding, pulverizing) and due to heat induced trans- to cis-
isomerization57.   
The absorption rate in the stomach and duodenum also affects the bioavailability of 
lycopene. The action of bile salts and pancreatic lipases assist in the digestion process. Lipids 
play an important role in lycopene dissolution and absorption. Lipid droplets containing the 
lycopene enter the duodenum and transfer into the mucosal cells via passive diffusion 19, 39, 58.  
Chylomicrons carry lycopene from the intestinal mucosa to the blood stream via the lymphatics 
39, 58.  Lycopene is transported in the plasma by lipoproteins, and is concentrated in the 
hydrophobic core of the lipoprotein particle 39.  Experimental studies have been conducted that 
suggest it is important to consider bioavailability and food product choice in designing 
interventions with lycopene.55, 56, 59-61  
Experimental studies of dietary lycopene in healthy adult subjects have been used to 
test the impact of lycopene on a number of variables. Two common themes are evident in 
these intervention studies (See Table 2-1).  First, when an increased amount of dietary lycopene 
is consumed there is a corresponding increase in the plasma level of lycopene60, 61.  Second, 
findings from these studies indicate an increased amount of dietary intake of lycopene 
Lycopene Interventions in Healthy Individuals 
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consistently decreases biomarkers of inflammation (CRP levels) and biomarkers of oxidative 
stress (lipid peroxidation)57, 60, 62-64.  As well, several small studies have demonstrated the 
variations of the bioavailability of lycopene, specifically in different food sources and when 
delivered in different mediums (canned vs. raw, paste vs. juice, olive oil vs. sunflower oil) 65, 66.  
Investigators have tested lycopene bioavailability and absorption rates and studied a 
variety of food products containing lycopene, but only in very small sample sizes.60, 61, 66-68 For 
example, the investigators in one intervention study tested 11 healthy individuals to determine 
whether consumption of diced tomatoes cooked with olive oil resulted in higher plasma 
lycopene concentrations than consumption of diced tomatoes cooked without olive oil67. 
Plasma lycopene concentrations were measured after 5 days of a lycopene washout period and 
again after a five-day dietary intervention.   The investigators concluded that the addition of 
olive oil to tomatoes greatly increased the absorption of lycopene as demonstrated by an 82% 
increase in plasma trans-lycopene (P = < 0.001) and a 40% increase in cis-lycopene (P = 0.002) 
concentrations67.  A smaller intervention study conducted in Northern Ireland with 6 healthy 
individuals tested two types of cooking oil with lycopene containing food products (tomato 
soup and canned tomatoes)68. The consumption of tomato products with olive oil significantly 
raised the plasma antioxidant activity from 930 ± 150 to 1118 ± 184 mmol/l, (p = .01) but no 
effect was observed when the sunflower oil was used 68. This investigation suggests the 
composition of oil used for cooking tomato products may affect the antioxidant activity and 
bioavailability of lycopene.  
Healthy individuals (n = 60; 30 men/30 women) who consumed a lycopene-free diet for 
1 week were randomized to receive lycopene from eating Campbell's Condensed Tomato Soup , 
13 
 
Campbell's Ready To Serve Tomato Soup  or V8 Vegetable Juice , respectively, for 15 days60.  
After the intervention period, total lycopene concentrations significantly increased for those 
consuming condensed soup, ready to eat soup and V8 [by 0.784 ± 0.083 (123% increase, P < 
0.0001), 0.545 ± 0.061 (57%, P < 0.01) and 0.569 ± 0.061 (112%, P < 0.0001) micro mol/Liter] 
when compared to baseline levels, respectively60. This study demonstrates that serum lycopene 
concentration changes as a result of intake of a variety of food products 60.  Collectively, these 
small intervention studies provide evidence to support the following when designing future 
experimental studies: 1) the anti-inflammatory effect of lycopene; and 2) the importance of 
considering bioavailability, food source and delivery medium when using dietary sources of 
lycopene. 
 Several large epidemiologic studies have been conducted. The combined evidence from 
these studies suggests an inverse relationship between serum carotenoids in general and 
lycopene specifically and cardiovascular disease risk69-73.  In a large prospective, longitudinal 
study of US male physicians, an association was found between increased vegetable intake and 
lower risk of coronary heart disease, independent of other cardiac risk factors 74. Investigators 
were able to detect a 25% risk reduction even at the low end of vegetable consumption (1-2 
servings per day). Similar findings from Ness et.al23 and Law et.al75 lend support to the findings 
in the Physician Health study.  Cross sectional data from the National Health and Nutritional 
Survey III (NHANES) 1988-1994 demonstrated an association between levels of five carotenoids 
(lycopene included) and inflammation measured by CRP76. The NHANES data were from a large 
sample (n = 4557) of young (mean age = 38.6 ± 8.6) healthy individuals. While these studies do 
Epidemiologic Studies of Lycopene   
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not specifically identify lycopene as a micronutrient of interest, nor do they specify HF as a 
condition, there is enough evidence from these studies to provide a foundation for additional 
inquiry related to the purpose of this paper.  
Methods 
The purpose of this paper was to examine the evidence about the impact of lycopene 
dietary interventions in patients with HF. A search of Pub Med, CINAHL, and the Cochrane 
Library was performed using the search terms ‘lycopene’, ‘antioxidants’, ‘heart disease’, ‘heart 
failure’, ‘oxidative stress’, and ‘inflammation.’ The search was limited to the time period 
between the years of 2000-2010 and to articles written in English. The following were inclusion 
criteria: 1) research reports; 2) human studies; 3) observational studies of dietary lycopene 
intake in patients with HF; 4) intervention studies of lycopene; and 5) dietary intake of food 
products containing lycopene, not supplements. Each manuscript was read and reviewed for 
content and applicability. The PubMed search resulted in the following results for each term 
used: (See Table 2-2) 
• lycopene = 2682 articles 
• lycopene and heart disease =104 articles  
• lycopene and inflammation = 36 articles 
• lycopene and oxidative stress = 304 articles 
• antioxidants and HF = 2371 articles 
• lycopene and  HF =3 articles 
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Results 
There were no intervention studies of dietary lycopene intake in patients with HF. Only 
two studies have been conducted that lend support for the potential role of dietary lycopene in 
patients with HF to reduce inflammation as evidenced by measurement of biomarkers of 
oxidative stress. 77, 78  
  A case-control evaluation of patients with HF moderate (class II) and severe (class III) HF 
according to NYHA classification (13 females, 17 males, 73.8 ± 7.4 years old; n= 30) were 
compared to age-matched controls (25 females, 30 males, 76.3 ± 8.5 years old; n = 55).77  
Investigators measured a circulating biomarker of oxidative stress (malondialdehyde-MDA) and 
plasma antioxidants (Vitamin A, E and carotenoids) levels. Significantly higher levels of oxidative 
stress and lower levels of plasma antioxidants were found in HF patients in comparison to 
controls. Levels of oxidative stress were found to be higher in New York Heart Association 
(NYHA) class III than in NYHA class II HF patients (p =.0012)77.  The conclusion from this 
particular investigation indicates an association exists between increased oxidative stress and 
the general class of antioxidant carotenoids in patients with HF.  
In a similar cross-sectional analysis (perhaps the same) by the Polidori et.al78, patients 
with moderate (class II) and severe (class III) HF according to NYHA classification, (14 male, 16 
female, 73.1 ± 7.4 years; n =30) were compared to age-gender matched controls (18 male, 12 
female, 80.0 ± 17.4 years; n= 30)78 and were found to have significantly higher levels of plasma 
F8, 12-isoprostanes. Isoprostanes are sensitive and specific markers of lipid peroxidation.  
Levels of 8, 12-isoprostane F(2α)-VI were significantly higher in class III than in class II NYHA HF 
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patients. The investigators also found the EF of HF patients to be inversely correlated to 
isoprotane levels and directly correlated to plasma levels of lycopene.  
These two studies, conducted by the same investigator, which had small sample sizes, 
did find significant associations between plasma lycopene, biomarkers of oxidative stress and 
the data do provide insight into the potential role of dietary lycopene to manage oxidative 
stress in patients with HF.  
In these small studies, investigators observed an association between HF patients and 
two types of biomarkers of oxidative stress. The age of the patients in these studies is 
representative of other HF samples. The sample would have been more inclusive if class I and 
class IV NYHA patients were included in the analysis, as I-IV is representative of the complete 
trajectory of HF disease status. Multiple drug therapies such as ACE inhibitors, beta blockers 
and diuretics were considered in only one of the studies; this is of importance as many of these 
drugs are considered to have antioxidant properties and could have confounded the results 
when considered as a co-variate in the analysis.  No differences were observed in these two 
studies between HF patients with an ischemic or non-ischemic etiology. The investigators 
excluded patients if they were smokers; this information would have added to the analysis as 
smoking history appears to have an association with antioxidant status.79, 80  
Critique 
The observation of a significant association between EF of HF patients and plasma levels 
of lycopene is of potential interest and warrants further studies in this area.  
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Discussion 
 After completing this review of the literature, it is interesting to note that further 
research has not been conducted and makes me wonder why this has not occurred. My 
conjecture for the reason why research has not advanced in this area is because “nutrition 
interventions” are not deemed as important as pharmacological interventions; there is not the 
same level of funding available for nutritional interventions as there is available for 
pharmacologic interventions. Specifically, I believe that medical practitioners are more 
interested in providing drugs to patients than they are in taking the time to explain the 
importance of nutrition and how patients with HF can make simple changes in lifestyle related 
to nutrition.  This conjecture is not evidence based, but is the experience of an advanced 
practice nurse with 20 years experience in caring for HF patients. The science of advancing 
treatment strategies for HF patients is primarily focused on pharmacologic interventions. The 
money for research is primarily available in pharmacologic studies. Hence, nutritional 
interventions appear to be designated to those individuals who have an interest in providing 
more than just pharmacologic treatment options to patients with HF.   
Conclusion 
In conclusion, there is sufficient evidence to support the following regarding lycopene 
and HF:   1) HF is a condition of increased inflammatory response; 2) oxidative stress poses an 
independent threat at the cellular level and contributes to the inflammatory response; 3) there 
are endogenous and exogenous antioxidant defense systems that can reduce the level of 
inflammation and oxidative stress; 4) lycopene is a potent antioxidant that is associated with 
reduced biomarkers of lipid peroxidation and oxidative stress. For the reasons elucidated, there 
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has been no research on the impact of dietary lycopene intake on inflammation in HF. Yet, 
given the safety of dietary lycopene intake and based on the known scientific foundation, it is 
plausible to begin scientific inquiry into the potential role of lycopene in reducing inflammation 
and oxidative stress in patients with advanced cardiovascular disease such as HF. This process 
of scientific inquiry will help to elucidate whether increased dietary intake of lycopene has a 
cardioprotective role in HF specific to inflammatory and oxidative stress components in the 
pathophysiologic process. 
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CHAPTER THREE 
Higher Dietary Lycopene Intake is Associated with Longer Cardiac Event-Free Survival in 
Patients with Heart Failure 
Introduction 
Heart failure (HF) remains a major cause of early death and is associated with high 
morbidity resulting in significant personal, societal and economic burden.82 Hospitalizations 
account for the majority of expenses incurred in the care of patients with HF. Rates of HF 
hospitalizations have increased by approximately 200% over the past decade.83 Additional 
strategies for managing HF are needed to reduce the personal and economic costs of HF.  
 Recent evidence suggests that nutrition may play a role in improving outcomes in 
patients with HF.13, 84-86 Findings point to specific macro and micronutrients that may slow the 
trajectory of HF by decreasing the inflammatory process associated with HF, and reducing the 
amount of oxidative stress.13, 48, 87, 88 Antioxidants such as lycopene, selenium and vitamin D 
may be targets for nutritional therapy. Lycopene in particular may be beneficial in HF due to 
potential cardioprotective effects. Numerous investigations in humans and animal models have 
demonstrated an inverse relationship between serum lycopene levels and risk of cardiovascular 
disease (CVD)62, 89-91. 
 The major source of dietary lycopene in the United States is fresh and processed fruits 
and vegetables, particularly tomatoes. Heat during processing alters the molecular structure of 
lycopene making it more bioavailable to human tissue39, 62, 92.  Unfortunately, processed foods 
containing high levels of lycopene also contain high levels of sodium. Research investigating the 
potential benefits of lycopene must also consider the sodium content of such foods93, 94. 
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Therefore the purpose of this study was to determine the association between lycopene intake 
and cardiac event-free survival in patients with HF stratified by sodium intake levels. 
Methods 
This was a longitudinal prospective study in which levels of dietary lycopene and sodium 
intake were measured at baseline. This study was part of a larger study titled “BMI, Nutrition, 
Inflammation, and Heart Failure Outcomes” (PI- Terry A. Lennie, R01NR 009280).  Patients were 
followed for up to three years. Rehospitalizations and cardiac mortality data were obtained to 
examine the relationship between dietary lycopene intake and cardiac event-free survival after 
stratifying patients by sodium intake levels.  
Study Design 
 Patients were recruited from outpatient HF clinics associated with academic health 
centers in Kentucky, Indiana and Georgia. Patients were included if they had a diagnosis of 
chronic HF confirmed by a cardiologist and were on a stable medication regimen for at least 3 
months. Patients were excluded if they had a history of acute myocardial infarction or 
cerebrovascular attack within the previous 6 months, were cognitively impaired, and had a co-
morbid terminal illness or an inflammatory condition that suppressed appetite or required 
dietary restrictions other than sodium. A total of 246 patients were invited to participate. Six 
patients declined, 7 patients withdrew, 5 patients were lost to follow-up and 16 provided 
incomplete food diaries resulting in a final sample size of 212 patients.  
Sample and setting 
Measurement of variables 
Dietary lycopene and sodium intake 
21 
 
Dietary intake was measured by four day food diaries that included three weekdays and 
one weekend day. Food diaries were analyzed using the Nutrition Data System for Research 
(NDSR; Nutrition Coordinating Center, Minneapolis, MN)95. The analysis provided four day 
averages of patient’s intake with data on 156 individual nutrients including lycopene and 
sodium.  
 The primary outcome of this study was event-free survival. This is defined as the 
composite end point of time to first HF hospitalization (emergency department or inpatient 
admission with a primary diagnosis of HF) or a cardiac related death during the follow-up 
period. Data on hospitalization events or death were collected from patients/ family member 
interviews, medical record review, hospital administrative records and death certificates. A 
clinical expert on the research team reviewed all the data on reasons for hospitalization to 
ensure accurate categorization. Because of the possibility that a patient was admitted to 
various hospitals, patients/families were interviewed to obtain self-reports of admissions, 
which were then used to validate or augment electronic medical record data. 
Event-free survival 
 Covariates included New York Heart Association (NHYA) functional classification, age, 
gender, body mass index (BMI) left ventricular ejection fraction (LVEF) and prescribed 
medications (i.e., ACE inhibitors, beta-blockers, angiotensin II receptor blockers, digoxin and 
diuretics). Total co-morbidity score was obtained using the Charlson Co-Morbidity Index 96, 97. 
Covariates 
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 The study received approval from the Institutional Review Board at each enrollment 
site. Patients with HF were referred to the study by cardiologists and nurse practitioners. All 
patients gave written informed consent prior to participating. Demographic and clinical 
characteristics were collected at baseline. Patients were visited in their homes by a trained 
research nurse who provided detailed oral and written instructions for recording all food and 
beverages consumed during the four day food diary collection. Digital scales were provided to 
measure the weight of each food. Food models were also provided for patients to estimate 
serving sizes when they found that weighing food was impractical (e.g., when eating at a 
restaurant). Patients were asked to provide a return demonstration of food diary recording and 
food measurement as a review of the procedure. Patients were also telephoned on the first day 
of the food diary recording to answer any questions they may have had. The morning after 
completion of the food diary, the patient met with the dietitian who reviewed the completed 
food diary. This process was to verify the serving sizes, obtain any missing information, and 
clarify food preparation techniques. These review sessions typically lasted 30-45 minutes. 
Lycopene and sodium levels were then determined using the NDSR software program for 
nutrient analysis. Lycopene and sodium daily consumption levels were totaled and then 
averaged over the four days of record keeping.  
Procedure 
 Data were analyzed using SPSS for Windows 17.0. Patients were dichotomized based on 
the median value for lycopene intake and the two groups were further stratified by the cut-
point of 3 grams of sodium intake. For the purpose of data analysis, patients with a lycopene 
Statistical Analysis 
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intake less than median were defined as low lycopene group and those with an intake of greater 
than median split were defined as the high lycopene group. Independent t tests or chi square 
tests were used to compare the differences of sample characteristics between lycopene groups. 
Cox proportional hazard regression was used to compare the differences in cardiac event-free 
survival of patients in the lycopene groups stratified by sodium intake while controlling for age, 
gender, HF etiology, BMI, NYHA classification, LVEF and total co-morbidity burden. The 
proportional hazard assumption was confirmed through visual inspection of the log (-log) 
survival curves.  
Results 
 Patient characteristics of the total sample and of the high and low lycopene intake 
groups are shown in Table 3-1. The average age of patients enrolled in this study was 60 years 
±12 (range 23-97 years). Sixty-eight percent of the patients were Caucasian and 29 % were 
African-American. Almost one-third of patients had preserved systolic function with LVEF > 
40%. The common co-morbidities were hypertension and diabetes mellitus. The mean four day 
average intake of lycopene was 4091 mcg/day ± 4940 (range from 0 - 31,529) and the median 
was 2471 (25th percentile = 915, 75th percentile = 5076) mcg/day. Fifty one percent of patients 
had daily sodium intake greater than 3 grams per day. The average sodium intake of the high 
lycopene group was greater than the low lycopene group (Table 1). The majority of patients in 
both lycopene groups were classified as NYHA functional classification of II or III, and were on 
appropriate HF medication regimens of ACE inhibitors, diuretics and beta blockers.  
Patient characteristics 
Cardiac events 
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 During the follow-up period there were a total of 2 patients who died (1.0%) and 41 
patients (19.3%) who were hospitalized with a primary diagnosis of HF or experienced a cardiac 
related death.  
Using Cox hazard regression modeling, patients with a dietary lycopene intake above 
the median had longer event-free survival than those with a dietary lycopene intake below the 
median after multivariate adjustment. In the stratum of patients with sodium intake levels 
above 3 grams per day, the low lycopene group demonstrated 3 times greater risk of having a 
cardiac event compared to patients in the high lycopene group (Table 2). Adjusted survival 
curves for high versus low lycopene groups with each stratum of sodium intake are depicted in 
Figure 1A and 1B. Higher intake of lycopene was associated with longer event-free survival in 
both strata of sodium intake. In the stratum of patients with sodium intake less than 3 grams 
per day, low lycopene intake presented a 3.3 times greater risk of cardiac events when 
compared to the high lycopene group.  
Discussion 
 This is the first study to demonstrate that higher intake of lycopene independently 
predicted longer cardiac event-free survival regardless of sodium intake in patients with heart 
failure. These findings are important because they suggest a fruitful avenue for future research 
that some have been reluctant to follow due to the high sodium content of many tomato-based 
foods. Our findings suggest that the antioxidant properties of dietary lycopene may be more 
important to the health of patients with health failure than reducing sodium intake alone.  
Our findings about lycopene are consistent with those of prior researchers who have 
reported inverse relationships between lycopene and the development of cardiovascular 
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disease (CVD)98.  The previous evidence in support of the role of lycopene in the prevention of 
CVD comes primarily from observational studies on normal and at risk populations. 3, 19, 62, 89, 91, 
99-101 
For example, in The Rotterdam Study, using a case-control design, investigators 
assessed the presence of calcified plaques in the abdominal aorta as a clinical indication of 
atherosclerosis4.  The study sample consisted of 108 individuals with moderate to severe 
atherosclerosis compared to 108 age-gender matched controls without atherosclerosis. The 
investigators reported an inverse relationship between serum levels of lycopene and the 
presence of atherosclerosis when using a logistic regression model with multivariate 
adjustment4.  The odds ratio for the highest compared to the lowest quartile of serum lycopene 
was 0.55 (95% CI, 0.25-1.22)4.  
The strongest population based evidence for lycopene comes from a multi-center case 
control study (EURAMIC) that evaluated the relationship between adipose tissue antioxidant 
status and acute myocardial infarction.70 Needle aspiration biopsy samples of the adipose tissue 
were taken after a myocardial infarction and levels of alpha carotene, beta carotene, lycopene 
and tocopherol were measured. Only lycopene was found to be protective with an odds ratio of 
0.52 for the comparison of the 10th and 90th percentiles (95% CI, 0.33-0.82; p = 0.005).70 A dose-
response was also observed between each quintile of adipose tissue lycopene and the risk of 
myocardial infarction.  The protective potential of lycopene was at the highest among 
individuals with the highest polyunsaturated fat stores70.  
Evidence about the effectiveness of lycopene in heart disease has recently been 
extended to patients with HF. In a series of observational studies, Polidori et al. evaluated 
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plasma levels of malondialdehyde (MDA) and F2 isoprostane as biomarkers of oxidative stress 
and antioxidants levels (vitamin A, vitamin E, lutein, zeaxanthin and lycopene) in 30 HF patients 
with NYHA Class II and III compared to 30 age-gender matched controls (18 male, 12 female, 
80.0 ± 17.4 years)77, 78.  Class II NYHA patients with HF had significantly lower levels of markers 
of oxidative stress (MDA and F2 isoprostane levels) and significantly higher levels of antioxidant 
intake (vitamin A, vitamin E, lutein, and lycopene) than NYHA III patients. Ejection fraction was 
inversely correlated with MDA levels in HF patients when compared to the controls. A positive 
correlation was found between plasma levels of lycopene, lutein and Vitamin A and ejection 
fraction, thus suggesting increased hemodynamic function of the heart in the presence of 
dietary antioxidants. These findings further suggest that antioxidants are depleted in patients 
with worse HF which may be linked to increased oxidative stress or perhaps as a result of 
lifestyle, disease or age-related reasons that can facilitate oxidative stress 77, 78. 
In a retrospective analysis of subjects enrolled in the Third National Health and Nutrition 
Examination Survey, Wood and Johnson reported a relationship was found between tomato 
consumption, serum lycopene levels and HF risk in individuals with periodontitis102. This dose-
response relationship existed after adjusting for demographic, medical and lifestyle factors (p = 
0.05). When data were further adjusted for serum lycopene levels, the relationship between 
tomato consumption and HF risk in periodontally involved individuals remained high (p = < .05) 
102. 
Approximately 80% of the sodium in the average American diet comes from processed 
foods and for the past two decades the average daily sodium intake among adults was greater 
than 3200mg103.  Dietary sodium indiscretion is considered to be a precipitant in >20% of 
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patients hospitalized for decompensated HF and high sodium intake is an independent risk 
factor for HF exacerbation104-106.  Because the richest sources of lycopene (processed tomato-
based products such as ketchup, tomato juice, and pizza and spaghetti sauces) are also some of 
the highest in sodium, clinicians commonly have patients with HF avoid these foods. Our data 
suggest that foods containing high levels of lycopene may be beneficial regardless of their 
sodium content.  
A potential limitation of this study was the use of self-recorded food diaries. We used a 
combination of strategies to increase the accuracy of the food diaries. Our participants were 
given detailed instructions for the diary by an experienced HF research nurse. In addition to the 
verbal instruction, written and graphic materials were provided to each participant. Patients 
also were given digital food scales to assist with measurement of food portions. Food models 
were utilized to help with estimation of serving sizes. Food diaries were reviewed with the 
patient by a dietician. Further motivation to accurately complete the food diary was enhanced 
by providing a nutritional analysis report to the patient. Another limitation to this study is that 
we did not obtain a direct measurement of oxidative stress or inflammation and therefore we 
cannot conclude the potential mechanism responsible for our findings.  
Our findings do support the potential cardioprotective benefit of higher lycopene intake 
in the presence of increased sodium levels in food products consumed by patients with HF. 
Increased sodium intake in patients with HF is associated with an increase in fluid retention that 
is often responsible for the exacerbation of HF symptoms. However, the potentially detrimental 
effect of increased sodium content in processed food products may not overshadow the benefit 
of lycopene in HF patients. However, further studies are needed to clearly delineate the 
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interaction of lycopene and sodium in patients with HF, and the results from our study should 
not be interpreted as suggesting that sodium restriction is unnecessary in patients with HF, 
even in the presence of high lycopene intake. 
Conclusion 
Future research should include use of randomized control trials of various levels of 
dietary lycopene intake in HF patients stratified by their usual sodium intake. A diet with a high 
lycopene intake has the potential to improve cardiac event free survival outcomes in HF 
patients. The study of dietary factors that lead to a diet rich in antioxidants is essential for 
optimization of interventions aimed at reducing the burden of HF. Additional research should 
be conducted to examine the potential impact of lycopene from a variety of food products on 
the inflammatory process in patients with HF. 
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CHAPTER FOUR 
Lycopene Dietary Intervention: A Pilot Study in Patients with Heart Failure 
Introduction 
Heart failure (HF) is recognized as a significant contributor to cardiovascular mortality 
and morbidity rates in North America and most Western civilizations and is considered one of 
the most problematic threats to healthcare. HF is commonly a result of ischemic heart disease 
or hypertension. Despite advances in the treatment of HF, the mortality and hospitalization 
rates for HF continue to rise with a 45% re-hospitalization rate at 6 months and a 27% re-
hospitalization rate at 90 days.107, 108 Over 800,000 hospitalization visits are reported annually 
by Medicare and these visits consume the majority of healthcare dollars required to care for 
patients with HF.109  
The connection between increased antioxidant intake and reduced cardiovascular 
disease (CVD) risk has been demonstrated in several epidemiologic and observational studies.1-4 
Although HF has a major inflammatory component and ischemic cardiovascular disease is the 
most common cause of HF, few investigators have examined the potential impact of increased 
antioxidant intake in improving outcomes in HF patients.  
There is substantial evidence to indicate that antioxidants play a role in reducing the 
inflammatory and oxidative stress processes that are thought to be responsible for 
atherosclerosis in CVD.110-112  Lycopene is a superior antioxidant found in natural and processed 
food products and is considered to be one of the most efficient at reducing free radicals.89, 113 
Given the role of inflammation in HF, a novel strategy for preventing or delaying the 
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complications of HF may be to increase lycopene intake in the diet. Thus, the purpose of this 
randomized, controlled pilot study was to test the effect of an intervention consisting of intake 
of a food product concentrated with lycopene (V8® juice) on biomarkers of inflammation and 
oxidative stress in patients with HF.   
Specific Aim #1: Compare the impact on serum levels of uric acid and C-reactive protein 
(CRP) in a group of patients with HF in the intervention group who consume 11 ounces of V8® 
juice daily to levels in a control group of HF patients who did not consume V8® juice daily 
controlling for HF severity as reflected by b-type natriuretic peptide (BNP). 
Hypothesis #1: Compared to a control group and to their own baseline, HF 
patients randomized to consume 11 ounces of V8® juice daily for one month will 
have lower levels of uric acid and CRP regardless of BNP level. 
Specific Aim #2: To test adherence to the intervention by comparing plasma levels of 
lycopene in the intervention versus control groups. 
Hypothesis #2:  Compared to a control group and to their own baseline, HF 
patients randomized to consume 11 ounces of V8® juice daily will have higher 
levels of plasma lycopene after one month of intervention. 
Specific Aim #3: To determine the impact of consumption of 11 ounces of V8® juice 
daily on sodium intake. 
Methods 
This study was a two-group randomized controlled intervention trial in which patients 
were randomized to either an intervention group (n=22) or usual care/control group (n=18). 
Study Design 
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Patients were recruited from outpatient and inpatient healthcare settings in Central Kentucky. 
The intervention group was given one 11.5 ounce can of V8® 100% Low-Sodium Vegetable juice 
to drink each day for 30 days while consuming  their normal habitual diet. The usual care group 
continued to consume their habitual diet. Data for both groups was collected at baseline and 
one month post intervention. Data collection included sociodemographic and clinical 
information, random 24 hour dietary food recalls, and blood samples for levels of uric acid, CRP, 
BNP and lycopene. 
Patients were recruited from a community hospital and an academic outpatient 
cardiology clinic in Central Kentucky.  Eligibility criteria for patients in this study included: 1) 
confirmed diagnosis of HF, with preserved or non-preserved ejection fraction, 2) hospitalized 
for HF within the last 6 months; 3) able to read and write English; 4) living independently (i.e., 
not institutionalized). Patients were excluded from the study if they: 1) were younger than 21 
years of age; 2) had end stage renal disease, a co-morbidity with a known inflammatory 
component, or a disease or illness that was predicted to cause death within the next 12 
months; 3) had impaired cognition; or 4) disliked V8 juice. Forty three patients were invited to 
participate in the study. Three declined to participate due to time constraints. No patients 
withdrew or were lost to follow-up during the one month time frame. The final sample size was 
40 patients. One baseline blood sample was dropped in the laboratory, therefore providing 39 
baseline samples of lycopene and 40 post intervention samples of lycopene.  
Sample and Setting 
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Measurement 
 Plasma lycopene was obtained from venous blood (approximately 5mL) that was drawn 
via needle and syringe from the lower forearm into EDTA vacutainer tubes (Fisher Scientific, 
Pittsburg, PA).  Plasma was immediately separated from red blood cells by centrifuging at 1000 
x g at 4˚C for 10 min.  Blood plasma was then placed into cryovials and stored at -80˚C until high 
performance liquid chromatography (HPLC) analysis. 
Plasma Lycopene 
Lycopene extraction:  Plasma (0.5mL) was mixed with 0.5mL ethanol containing 0.1% 
butylated hydroxytoluene and 2mL of HEAT (10 hexane/6 ethanol/7 acetone/7 toluene).  The 
mixture was vortexed and then centrifuged for 5min at 300 x g.  The upper non-polar layer was 
removed and the remaining aqueous plasma mixture was extracted twice more.  The three 
non-polar extracts were combined and dried under nitrogen.  The dried extract was stored at -
80˚C until HPLC-PDA analysis.  
Lycopene HPLC-PDA (photodiode array) analysis:  Samples were reconstituted in 1:1 
200µL methanol/ Methyl tert-butyl ether (MTBE) and filtered through a nylon syringe filter. 
Samples were analyzed using an HPLC system (Waters 996) interfaced with a PDA detector 
(Waters 2996).  Separation was achieved using a YMC C-30 column (Waters Corp., Milford, MA).  
A 30 min. gradient method employing methanol and MTBE was used with a flow rate of 
1.3mL/min, column temperature = 30°C, and injection volume = 20 µL.  Lycopene was 
quantified using an external calibration curve. 
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C-reactive protein was measured using point-of-care methodology (Cholestech LDX 
Diagnostics, Inverness Medical Innovations). Venous blood (approximately 5mL) was withdrawn 
via a needle and syringe from the patient and placed into a purple top vacutainer. Serum was 
removed from the vacutainers using a pipette, 0.4ml was placed onto the Cholestech hsCRP 
cartridge, then placed into the Cholestech LDX® analyser. The Cholestech LDX® system uses 
reflectance photometry. This method of determining CRP levels has been demonstrated to 
provide reproducible, accurate and valid results.114 
C-Reactive Protein 
Uric acid was measured using standardized laboratory assay analysis at the University of 
Kentucky clinical laboratory. Venous blood (approximately 5ml) was withdrawn via a needle and 
syringe from the patient and placed into a green top vacutainer. Samples were refrigerated as 
necessary and taken to the clinical research laboratory for analysis using.  
Uric Acid 
  B-type natriuretic peptide was measured using a point-of-care machine. Venous blood 
(approximately 5mL) was withdrawn via a needle and syringe from the patient and placed into a 
vacutainer tube. Serum was removed from the vacutainers using a pipette, 0.1ml was placed 
onto the Triage BNP cartridge, then into the Triage BNP® analysis machine (Biosite Diagnostics, 
Inverness Medical Innovations). This method of determining BNP levels has been demonstrated 
to provide reproducible, accurate and valid results.115 
B-type Natriuretic Peptide 
Sociodemographic and clinical characteristics 
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In order to characterize patients, they were interviewed and answered questionnaires 
to obtain the following information: age, gender, marital status, smoking history, exercise 
patterns, comorbid conditions, NYHA classification, lifestyle behaviors and current medications, 
including vitamins, over the counter drugs or herbal supplements. The research nurse collected 
information on comorbid conditions using the interview format of the Charlson Comorbidity 
Index (CCI)116, 117. This index was developed to classify comorbid conditions that might change 
the risk of mortality. The index predicts short-term and long-term mortality in several situations 
including patients with heart disease including HF, cancer, stroke, renal disease, and frail 
elders97, 117. 
Dietary nutrient intake of sodium and lycopene was assessed using a 24-hour diet recall 
method to determine (1) natural intake of lycopene in order to describe the lycopene intake in 
food products consumed in the control and intervention groups, and (2) sodium intake, as 
lycopene containing foods that are processed often contain higher levels of sodium.  A 24 hour 
diet recall was collected at the baseline data collection visit and then randomly once a week for 
3 weeks for a total of 4 recalls for each patient.  The research nurse provided each patient with 
detailed instructions on how the diet recall information would be obtained. The information 
provided during the 24-hour recall was recorded onto a secure laptop and then entered into a 
computer software program titled Nutrition Data System (NDS) software (NCC, University of 
Minnesota)
Dietary intake assessment 
118.  This program was used to analyze the nutrient content of the dietary recall. The 
NDS software provides output for 126 nutrient and nutrient ratios from the food intake data. 
The database, which is updated twice yearly, contains ingredient information for over 19,000 
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foods including over 8000 brand name and many ethnic foods118. There are data for over 
160,000 food variants differing in preparation method or ingredients. The research nurse 
collecting data completed a certification process as a nutrition interviewer using the NDSR 
software. 
The Institutional Review Board at the University of Kentucky granted permission to 
conduct this study. All patients gave informed written consent. A research nurse performed all 
procedures. The research nurse was an experienced cardiovascular advanced practice nurse 
who has completed certified training on protection of human subjects in research. During the 
first interview with the patients, the research nurse obtained sociodemographic and clinical 
data.  Data about medications and supplements was obtained from the patient and verified 
through a review of the medical record. The research nurse also determined patients’ New York 
Heart Association (NYHA) functional class by interviewing patients and determining their ability 
to perform their usual activities and the occurrence of any symptoms with those activities. The 
patient interview and questionnaires were completed at the baseline visit and again at the 
post-intervention visit one month later.  The visits took place at a prearranged time such as 
before or after a cardiology clinic visit, cardiac rehabilitation session, in their home or at a place 
of convenience the participant chose.  
Research Procedures  
Patients were randomized to one of two groups following completion of baseline data 
collection. A computer generated random number/block chart was utilized. Patients in both 
groups were given detailed instructions regarding 24-hour dietary recall.  Serving size 
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estimation charts were provided to patients to assist with accuracy in conducting diet recalls. 
The dietary recalls took between 15-20 minutes to complete.  
Patients randomized to the intervention group received a month’s supply of V8® 100% 
Low-Sodium Vegetable juice (30 cans). Patients were asked to consume one can each day. They 
were instructed that the entire can of juice could be consumed at one time or at separate times 
as long as the entire can was consumed each day. Patients were also asked to keep track of 
how many total cans they consumed during the month; this was to facilitate fidelity to the 
intervention.  V8® is vegetable juice, which is tomato based. Each 11.5 ounces of V8® juice 
contains the following:  24 mg of lycopene; 70 calories; 140 mg of sodium; vitamins  A and C;  
820 mg of potassium; 2% of the recommended daily allowance for iron and magnesium;  and 3 
grams of fiber. This product contains a variety of vegetables (i.e., tomatoes, carrots, celery, 
beets, parsley, lettuce, watercress, and spinach)
Intervention 
119. 
The research nurse reviewed all questionnaires for completeness and legibility while the 
patients were still present. All data analyses were conducted using SPSS version 17.0 and a P 
value of < .05 was considered statistically significant.  Descriptive analyses are presented as 
frequencies and means ± standard deviations as appropriate to the level of measurement of the 
variables. To compare baseline differences in sociodemographic and clinical characteristics 
between the two treatment groups, t-tests or chi-square were used. Intention to treat 
princip5les were applied to all data analysis. First, repeated measures ANCOVA was used to 
assess whether the changes over time in the outcome measures differed between the 
Statistical Analysis 
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intervention and control groups, controlling for BNP level. Then, multifactorial repeated 
measures ANCOVA was used to evaluate whether gender or BNP interacted with group to 
produce a differential impact on CRP and uric acid levels.  
Results 
Characteristics of the total group and of the groups compared are displayed in Table 1. A 
total of 40 patients who were all categorized as NYHA class II or III were enrolled. Most patients 
had an ischemic HF etiology.  There were no significant differences between patients in the 
control group or the intervention group with respect to age, gender, body mass index, HF 
etiology, NYHA classification, medications prescribed, smoking history or exercise patterns 
(Table 3-1). All patients who enrolled in the study completed the study. There was only one side 
effect reported in relation to drinking V8 juice daily and that was an increase in bowel 
movements.  
Patient Characteristics 
Repeated measures ANCOVA revealed that the intervention and control groups were 
similar on baseline measures of uric acid and CRP (Table 4-2). There were no differences at 
baseline or across time in the covariate, BNP, between or within the groups. There was no 
impact of the intervention on uric acid or CRP levels and there were no changes across time in 
the control group in uric acid level or CRP (Table 4-2).   
Specific Aim 1 
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Multifactorial repeated measures ANCOVA revealed that there was a gender by group 
by time effect on CRP (p = 0.024 for the interaction; Figure 1), but not uric acid (p > 0.05 for 
interaction and main effects; Figure 4-2) levels. There was no effect of the covariate, BNP level. 
Among women in the intervention group there was a significant decrease in plasma CRP levels 
at the post-intervention time point. There was no change in CRP levels among men in the 
intervention group, but there was a decrease across time in the control group (Figure 4-1). 
In order to explore potential reasons for the gender difference in the impact of the 
intervention, we compared men and women on baseline BMI and CRP levels. There were no 
differences between women and men in BMI (31.9 ± 9.7 vs 30.7 ± 6.7, respectively; p = 0.638).  
There were difference in CRP levels between women and men (5.69 ± 3.5 vs 2.86 ± 2.62, 
respectively; p = 0.01).   
Plasma lycopene levels significantly increased in the intervention group after daily 
consumption of V8® 100% vegetable juice for 30 days, while there was no change in the control 
group (See Figure 4-2; p = 0.02).  There was no interaction of gender and group with regard to 
the effect of the intervention on lycopene levels (p = 0.37).  Plasma lycopene levels increased in 
both men and women over time in the intervention group, but not in the control group. 
Specific Aim 2 
 There was no significant group by time interaction on sodium intake (See Table 3; p = 
0.237).  There was no main effect of either time or group on sodium intake (Table 3, p = 0.153). 
Specific Aim 3 
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Discussion 
This is the first study in which a dietary lycopene intervention has been tested in a 
sample of patients with HF. To date, there have been only two other studies in which the role of 
dietary lycopene in patients with HF was assessed. In both studies, there was a positive 
association between plasma lycopene levels, oxidative stress and HF77, 78, but both of these 
studies were observational. In order to come to any firm conclusions about the effect of 
lycopene in patients with HF, randomized, controlled studies are needed. 
In our randomized, controlled study, we did not see an impact of the intervention on 
either CRP or uric acid levels in the total group. We did, however, see a differential effect of 
gender in the effect of the intervention on CRP levels, but not uric acid. In women, the 
intervention resulted in a significant decrease in CRP across time, but not in men. 
There are three major potential explanations for our finding of a gender effect in the 
intervention. The possibilities include (1) greater adherence to the intervention in women than 
in men, (2) the effect of BMI and adiposity, and (3) the higher CRP levels seen in women. With 
regard to the first potential explanation, there is published evidence that women are more 
adherent to prescribed HF regimens than men.120 There was, however, no evidence in our 
sample that women were more adherent than men. Lycopene levels increased significantly in 
both men and women in the intervention group over time, while remaining unchanged in the 
control group.  
With regard to the second potential explanation for our findings, increased BMI and 
adiposity found in women may be plausible reasons. The adipose tissue produces inflammatory 
cytokines such as interleukin-6 and tumor necrosis factor-alpha, which contribute to 
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atherosclerosis. IL-6 enhances liver production of CRP. Levels of inflammatory markers in obese 
persons (BMI > 30 kg/m2) are considered independent predictors of CVD. Lycopene increases in 
adipose tissue and may exert its action on inflammatory cytokines.  Abdominal adiposity has 
been associated with risk of CHD in women121, 122. Higher waist-hip-ration (WHR) and greater 
waist circumference have been found to be independently associated with a significantly 
increased age-adjusted risk of CVD and HF.121, 123, 124 In the Nurses’ Health Study, women with a 
WHR of 0.88 or higher had a relative risk (RR) of 3.25 (95% confidence interval, 1.78-5.95) for 
CVD compared with women with a WHR of less than 0.72.121   There was no gender difference 
in BMI level in our sample of patients. However, we did not have a measure of abdominal 
adiposity, most commonly measured by waist circumference or WHR. This additional 
measurement may have shed additional light onto our findings.  
With regard to the third potential explanation for our findings, women have higher 
levels of CRP than do men.125 For example, women participants enrolled in the Women’s Health 
Study had a median CRP level of 0.42mg/dL compared with 0.28mg/dL in men.126 In our sample, 
women had significantly higher baseline CRP levels than men.  Often, the effect of a variety of 
interventions (e.g., cardiac rehabilitation, weight loss, intake of healthy foods) is greater in 
those in whom the outcome of interest is most negatively affected. That is, those who have the 
most to gain (or lose), often show the largest effects of an intervention, at least initially.127-132 
Thus, it is plausible that the substantially higher levels of CRP seen in the women in our study 
allowed the intervention to better exert its effects. 
There is sufficient evidence to support that CRP plays a direct role in inflammation. 133 
The fact that our study found CRP levels decreased in response to a dietary intervention is a 
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positive finding. Any decrease in CRP levels, such as the one observed in our study, has the 
ability to reduce the risk of further cardiac events and is considered to be of important value to 
clinicians and patients. 125, 134 A CRP in the highest quartile >0.73mg/dL had a five times greater 
risk of developing an acute myocardial infarction or stoke compared to those in the lowest 
quartile.126  CRP levels have also been shown to predict mortality in patients with dilated 
cardiomyopathy and to have an inverse association with left ventricular function in patients 
with HF.135 136   If CRP levels have increased in patients affected by HF, they will further increase 
with the severity of the pathology and be associated with a higher rate of mortality 
independently of any ischemic cause.46, 136  
Our data also indicate that increased consumption of lycopene containing food products 
results in increased plasma levels of lycopene. These data support other findings that increased 
dietary intake of lycopene is reflected in plasma samples, indicating the bioavailability of 
lycopene in human plasma57, 60, 137.  Adherence to the lycopene intervention was observed in 
both women and men in our sample.  
Uric acid levels did not change as a result of the intervention, suggesting serum uric acid 
may not be a robust indicator of oxidative stress in patients with HF. High serum uric acid levels 
have been identified as a strong, independent marker of impaired prognosis in patients with 
moderate to severe CHF138.  Uric acid excretion depends on renal function and may be 
compromised by diuretic treatment in these patients. The increased accumulation of reactive 
oxygen species (ROS) as a by-product of xanthine oxidase activity, is thought to be one of the 
underlying pathologic characteristics of increased uric acid in HF139.  Inflammatory immune 
activation and increased ROS accumulation (See Figure 4-Pathway of Inflammation and 
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Oxidative Stress”), along with up-regulation of xanthine oxidase activity may contribute to 
oxidative stress found in the setting of HF140 141.  However, our study did not find serum uric 
acid to be robust indicator of oxidative stress in a sample of patients with HF. This may be a 
result of the small sample size or that uric acid production occurs upstream in the pathway of 
oxidation and inflammation (See Figure 4).  
Processed foods containing high levels of lycopene also contain high levels of sodium. 
Approximately 80% of the sodium in the average American diet comes from processed foods. 
Dietary sodium indiscretion is considered to be a precipitant in >20% of patients hospitalized 
for decompensated HF and high sodium intake is an independent risk factor for HF 
exacerbation. 104-106 Data from an earlier investigation suggest that foods containing high levels 
of lycopene may be beneficial regardless of their sodium content142 The findings in the current 
study did not indicate an increase in sodium intake between the two treatment groups. 
However, even if a small increase in sodium levels had occurred, the benefit of the strong 
antioxidant lycopene used in the intervention may not have had a negative impact on patients 
with heart failure.  
 An important challenge in translating these findings into clinical treatment strategies 
relates to the fact that most clinical studies have been designed on top of established 
pharmacological therapy, whereas most experimental studies test novel interventions without 
concomitant drug regimens such as ACE inhibitors or beta-blockers. However, our study tested 
a randomized intervention on top of evidence-based drug regimens for patients with HF and 
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still found an impact of a dietary intervention. This is exciting and demonstrated a fruitful area 
of additional research related to dietary lycopene interventions.  
With regards to the feasibility of this randomized, controlled trial of a dietary 
intervention with lycopene, we found patients with HF were able to adhere to the intervention 
as evidenced by a compliance rate of 100%. We also found this was an easy and inexpensive 
intervention to implement. The V8® juice cost less than $1.00 per serving and is found in most 
urban and rural grocery stores. The patients did not report any ill effects from drinking the 
lycopene product for 30 days and only one person reported a mild side effect of increased 
bowel movements. This intervention was a simple and easily implemented dietary intervention 
and was well accepted and followed by a sample of patients with difficult self-management 
regimens.  
Limitations exist when investigating the impact of a single micronutrient in a complex 
condition such as HF. First, this investigation was a conducted in a small sample of patients with 
HF. A larger sample size may assist in understanding mechanistic pathways for the interaction 
we observed. A larger sample also needs to be studied in order to confirm the presence of a 
gender interaction with the intervention. Secondly, the biological measurements that were 
obtained in this study were collected at only two different time points and may not be 
reflective of overall inflammatory status or oxidative stress in patients with HF.  
Limitations 
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The study of the role of dietary or whole food sources of micronutrients as interventions 
for inflammation and oxidative status in patients with HF is novel. To date, investigators have 
largely studied supplements as sources of micronutrients. Lycopene is a natural plant 
compound found in fruits and vegetables. Lycopene-containing products are inexpensive, 
readily available, shelf-stable, and versatile. In a sample of patients with HF who received a 
dietary lycopene intervention, we found a significant increase in plasma lycopene levels. Serum 
CRP levels, as a biomarker of inflammation, significantly increased in the intervention group but 
within females only. These findings suggest the naturally occurring antioxidant lycopene 
interacts with gender to affect CRP levels in a sample of patients with HF. Although a 
physiologic mechanism is unclear, additional studies will help clarify this finding. This study 
provides insight to the potential role of lycopene in HF and may lead to additional treatment 
strategies. These findings are a preliminary step in a process of establishing efficacy of a specific 
dietary intervention with antioxidants that may have an effect on inflammation and oxidative 
stress in HF. 
Conclusion 
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Chapter Five 
Conclusions and Discussion  
 
 The enormous impact heart failure (HF) places on individuals and on our healthcare 
system continue to drive the search for cost-effective treatment strategies. HF affects nearly 6 
million people in the United States alone and the number of new cases is expected to increase 
by more than 600 thousand cases each year.8, 9  Projected medical costs for the treatment of HF 
are expected to increase by approximately 200% by the year 2030.143 Current treatment 
strategies include multiple drug regimens with the evidenced-based use of angiotensin-
converting enzyme inhibitors (ACE), beta-blockers (BB), diuretics, and spironalactone.144  
Invasive procedures for the treatment of HF include placement of implantable cardio-
defibrillators (ICD) and cardiac resynchronization therapy (CRT).144 Both of these strategies 
account for the high costs related to treatment of HF. In addition to rising treatment costs, 
there is an increase in the number of patients with HF due to the overall aging of the 
population.143 Cumulatively, these issues are the momentum for researchers to find novel 
therapeutic and economical interventions that are easily combined with current treatment 
strategies.  
 The overall goal of treatment for HF is to reduce the substantial symptom burden that 
accompanies HF. HF is a condition of chronic exacerbations of volume overload and myocardial 
injury resulting from an intricate relationship between biochemical and biological mechanisms. 
Recent research has provided evidence that inflammation and oxidative stress contribute to the 
development and progression of HF.40, 145  
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Inflammation and oxidative stress, independently and mutually, can reduce myocardial 
contractility leading to a reduction in cardiac index. At the cellular level, inflammation increases 
endothelial dysfunction via an inflammatory pathway activated by direct antigenic stimulation 
or cytokine release in response to hemodynamic stress.42, 48, 50 Inflammatory cytokines, once 
thought to be produced solely by the immune system, are now known to be synthesized by the 
cardiomyocyte and can stimulate myocardial dysfunction by remodeling of the myocardium 
interstitium through myocyte hypertrophy, apoptosis, and endothelial damage. 146, 147 
Oxidative stress is the outcome when there is an imbalance between the reactive 
oxygen species (ROS) production and the antioxidant defense mechanisms in the body.112, 148, 149 
Oxidative injury occurs when the system is overwhelmed by free radicals and modification 
occurs to organic molecules.112, 150, 151  Antioxidants provide protection by scavenging and 
detoxifying the free radicals, thus maintaining a homeostatic balance at the cellular level.47, 152 
Antioxidant nutrients may slow the progression of HF because of their ability to inhibit 
damaging oxidative and inflammatory processes. Chapter two of this dissertation was a review 
of the current research literature related to antioxidants and heart failure. Specifically, I 
reviewed the literature to identify any investigations with the antioxidant lycopene used as a 
dietary intervention with HF patients. As a result of this review, I found that there were no 
intervention studies using lycopene in patients with HF, but that there to be strong evidence to 
support the role of antioxidants in cardiovascular disease.69, 71-73, 113 I also found strong evidence 
supporting the role of inflammation and oxidative stress for improving outcomes in patients 
with  HF40, 50, 112, 145, 150, 153, 154.    Several studies have been conducted with lycopene and other 
antioxidants in healthy individuals and an inverse relationship has been observed between 
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increased lycopene intake and cardiovascular disease risk.59, 60, 62, 63, 67, 89, 101, 155-158  To date 
there have been two case-control studies in which lycopene was investigated as the variable of 
interest in a sample of HF patients.77, 78 Significantly higher levels of oxidative stress and lower 
levels of plasma antioxidants were found in HF patients in comparison to controls. Among HF 
patients, and ejection fraction (indicating disease severity) was found to be inversely correlated 
to isoprotane levels (biomarker of oxidative status) and directly correlated to plasma levels of 
dietary lycopene.77, 78  Collectively, these data provide evidence for the potential role of dietary 
antioxidants in reducing nflammation and oxidative stress, thus potentially reducing symptom 
burden in patients with HF.  
Chapter three of this dissertation is a longitudinal prospective study in which levels of 
dietary lycopene and sodium intake were measured. Rehospitalizations and cardiac mortality 
data were obtained to examine the relationship between dietary lycopene intake and cardiac 
event-free survival after stratifying patients by sodium intake levels. Dietary intake was 
measured by four-day food diaries. Food diaries were analyzed using the Nutrition Data System 
for Research (NDSR; Nutrition Coordinating Center, Minneapolis, MN).95 Patients were grouped 
by the median split of lycopene level of 2471 mcg/day and stratified by daily sodium intake 
levels above and below 3 grams. Patients were followed for up to three years to collect data on 
HF hospitalization and cardiac mortality for event-free survival analysis. Cox proportional 
hazard regression was used to compare differences in cardiac event-free survival between 
higher and lower lycopene intake groups within each stratum of sodium intake level. Lycopene 
intake above 2471 mcg/day was associated with longer cardiac event-free survival compared 
with lower lycopene intake after controlling for age, gender, HF etiology, body mass index, 
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NYHA functional class, LVEF, and total comorbidity score (p = .003). The worst cardiac event-
free survival was observed in the low lycopene intake group regardless of sodium intake level (> 
3 grams HR = 3.01; p = .027 and < 3 grams HR= 3.34; p = .023). These data suggest an increased 
dietary lycopene intake has the potential to improve cardiac event-free survival in patients with 
HF independent of sodium intake, thus lending support to the role antioxidants may have in 
patients with HF.  
An intervention study was designed to test the impact of dietary lycopene on 
biomarkers of inflammation and oxidative stress specifically in patients with HF. This study is 
addressed in Chapter Four of this dissertation and was supported by the consistent protective 
effect of lycopene found in epidemiological, tissue and experimental studies.  
 A randomized-control feasibility trial was conducted with a sample of 40 HF patients 
assigned patients to one of two groups.  The lycopene intervention group received 24 mg of 
lycopene intake per day by drinking an 11.5 ounce serving of V8 100% vegetable juice daily for 
30 days.  Group 2 (usual care) continued their usual diet.  Four randomized phone calls were 
used to collect 24 hour diet recalls from the patients.  We obtained serum lycopene, uric acid 
(biomarker of oxidative stress), C-reactive protein (biomarker of inflammation), and b-type 
natriuretic peptide (biomarker of HF disease severity) to determine the impact of the lycopene 
dietary intervention.  
In this study we used repeated measures ANCOVA to assess whether the changes over 
time in the outcome measures differed between the intervention and control groups, 
controlling for BNP level. Then, multifactorial repeated measures ANCOVA was used to evaluate 
whether gender or BNP interacted with group to produce a differential impact on CRP and uric 
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acid levels. We also used repeated measures ANOVA to test the impact of the intervention by 
gender. The results of this investigation found plasma lycopene levels increased insignificantly 
in the intervention group compared to the control group respectively (.51mmol/L to 
.76mmol/L, p = .002; .56mmol/L to .58mmol/L.  There was also a significant interaction 
between CRP group and gender in the impact of the intervention on CRP levels; CRP levels 
decreased significantly in the intervention group in women and but not in men, (p = .024).  Uric 
acid and BNP did not demonstrate a change related to the intervention as hypothesized in this 
study. These findings suggest the naturally occurring antioxidant lycopene interacts with gender 
to affect inflammation, as measured by CRP, in an intervention of increase dietary lycopene in a 
sample of patients with HF.  
The feasibility study and the longitudinal study combined are the beginning of a 
program of research specifically focusing on the potential role of dietary lycopene in reducing 
inflammation and oxidative stress in patients with HF. The potential impact of a dietary 
intervention to reduce symptom burden in HF is of great interest to clinicians and researchers 
as it poses a novel, innovative treatment strategy. A dietary intervention with a food product 
high in lycopene, such as V8 juice once a day, is an economical and easily combined treatment 
strategy with, very limited, if any side effects for patients with HF.  
Additional studies are needed to further identify physiologic mechanisms of lycopene 
and to identify appropriate biomarkers to measure oxidative stress and inflammation in chronic 
HF as these remain unclear. Larger samples of patients with HF should be studied to validate 
the findings from the feasibility study.  Antioxidants other than lycopene may be responsible for 
the impact of the intervention, or it may be a combination of antioxidants found in V8 juice. A 
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thorough examination of specific antioxidants and combined antioxidants should be conducted 
in similar studies.   
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Table 1-1: Definition of Terms- obtained from Taber’s Cyclopedic Medical Dictionary, 
Nineteenth Edition 
 antioxidant
 
- a agent that prevents or inhibits oxidation. A substance that may protect cells 
from the damaging effects of oxygen radicals, highly reactive chemicals that play a part in 
atherosclerosis, some forms of cancer, and reperfusion injuries.   
bioactive
 
- affecting living tissues 
biochemical- of or related to biochemistry, the chemistry of living things, the science of 
chemical changes accompanying the vital functions of plants and animals 
carotenoid- one of a group of more than 500 yellow, orange, or red fat soluble pigments found 
naturally in fruits and vegetables and acting as antioxidants in the body 
endogenous- produced or originating from within a cell or organism 
inflammation- an immunological defense against injury, infection or allergy, marked by 
increases in regional blood flow, immigration of white blood cells, and release of chemical 
toxins 
micronutrient- any of the chemical elements required in minute quantities for growth of an 
organism 
nutrient- a nutritious ingredient or substance in food 
nutrition- the series of processes by which an organism takes in and assimilates food for 
promoting growth and replacing worn or injured tissues 
oxidation- any process in which oxygen combines with an element or substance 
peroxidase- any oxioreductase enzyme that acts as a catalyst in reactions in which a peroxide is 
reduced 
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peroxide- any oxide containing the O2 group in which the two atoms of oxygen are linked by a 
single bond 
phytochemical - chemical processes associated with plant life, and the chemical compounds 
produced by plants 
reactive oxygen species- a phrase used to describe a variety of molecules and free radicals 
(chemical species with one unpaired electron) derived from molecular oxygen. Molecular 
oxygen in the ground state is a bi-radical, containing two unpaired electrons in the outer shell 
(also known as a triplet state). If one of the two unpaired electrons is excited and changes its 
spin, the resulting species (known as singlet oxygen) becomes a powerful oxidant as the two 
electrons with opposing spins can quickly react with other pairs of electrons, especially double 
bonds. 
scavenger - anything that removes impurities or refuse 
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Table 2-1: Dietary intervention studies with Lycopene in healthy Individuals 
Study Author Subjects Type and duration of intervention  Results 
Agarwal et. al, 
200157 
20 healthy individuals 
10 male 
10 female 
Randomized crossover design 
Placebo= 0 mg lycopene 
Tomato juice = 50mg lycopene (500 ml) 
Spaghetti sauce = 40 mg lycopene (126 g)  
1) Daily intake of spaghetti sauce or 
juice significantly increased serum 
levels of lycopene. 
2) the avg. increase of any dietary 
treatment over placebo was 2-fold 
3) dietary lycopene significantly 
lowered lipid oxidation measures 
(TBARS) 
 
Bose & 
Agarwal, 
200762 
50 healthy & 
30 CHD  
Selected to 
intervention 
200 g cooked tomatoes = 25mg of lycopene 
60 days 
1)Significant improvement in serum 
levels of enzymes involved in 
antioxidant activity 
2) Decreased lipid peroxidation rates 
3) No significant changes in lipid 
profiles 
Hadley, et.al 
200360 
60 healthy 
Randomized to 
intervention 
1) Campbell’s condensed soup =35mg lycopene  
2) Campbell’s ready to serve soup= 23mg 
lycopene 
3) V8 juice = 25mg lycopene 
15 days 
1) Increased protection of 
lipoproteins to oxidative stress 
2) Lycopene isomers change rapidly 
with variation in dietary intake 
Jacob, et.al 
200863 
24 healthy 
Randomized to 
intervention 
1) 250 ml tomato juice with 90mg of Vit C twice 
daily 
2) 250 ml of tomato juice with 870mg Vit C 
twice daily-  
14 days 
1)Reduction in serum total 
cholesterol levels and CRP with 
tomato juice consumption in both 
groups 
2) Cholesterol reduction correlated 
with lycopene uptake 
Bub, et.al 
200064 
23 non-smoking men 
 
Feeding study 
1) 2 week intake of low carotenoid content 
2) 2 week intake of 330 ml tomato juice=40mg 
lycopene 
3) 2 week intake of 330ml carrot juice= 15.7mg 
α-carotene & 22.3mg β-carotene 
4) 2 week spinach powder = 11.3mg of lutein 
and 3.1mg β-carotene 
8 weeks  
 
1)Tomato juice consumption 
increased TBARs by 12% and 
increased lag time for lipoprotein 
oxidation- reducing LDL oxidation 
2) Carrot juice and spinach powder 
had no effect on lipid peroxidation 
 
Frohlich, et.al 
200561 
17 non-smoking 
volunteers 
Randomized to 
intervention 
1) 145-320 g tomatoes/day = 12.5mg lycopene 
2) 94-101 g tomato juice/day = 12.5mg 
lycopene 
3) 25-28 g tomato puree/day = 12.5mg 
lycopene 
4 weeks 
1) Following intervention, plasma 
lycopene increased significantly 
2) Supplementation did not affect 
levels of tocopherols and ascorbic 
acid in plasma 
3) Lycopene isomerization changes 
within the body after ingestion 
Unlu, et.al 
200581 
11 healthy non-
smoking subjects 
Feeding study 
1) 300g Salsa w/avocado and w/o avocado    & 
3 slices of fat free bread 
2) 220g Salad with carrots, lettuce, baby 
spinach & 40g fat free Italian salad dressing 
with 2 slices of fat-free bread-8 weeks 
1) Lycopene  and β- carotene 
absorption from salsa with avocado 
was significantly higher than the 
control meal 
 
Van het Hof 
et.al 200065 
33 volunteers, divided 
into 2 groups by 
gender 
Split plot design- heat treatment and 
homogenization 
A pasta meal served at lunch for 4 cons. days 
(no other fruits or vegetables were served on 
these days) served with macaroni, ham and a 
white sauce and a dessert of custard 
1.canned tomatoes- 55 min of heat at 100 
degrees Celsius 
2.canned tomatoes- blended, homogenized 
and heated 
3. canned tomatoes- minimally heated at 80 C 
1) Additional heat and 
homogenization enhanced the 
release of lycopene; additional 
heating was not always significant. 
2) short term increased lycopene 
intake is a good model to compare 
the bioavailability from different 
food sources 
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Table 2-2:  Literature Search 
Search Terms PubMed CINAHL Cochrane 
Lycopene 2682 406 4 
Lycopene & HF 3 2 0 
Lycopene & oxidative stress 304 42 1 
Lycopene & inflammation 76 14 8 
Lycopene & heart disease 104 10 7 
HF & antioxidants 2371 55 1 
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Table 3-1: Patient characteristics N = 212 
 
Characteristics (%) or Mean ± SD 
 
Total  
(n = 212) 
Lycopene ≤ 
2471 mcg/day 
Lycopene > 
2471 mcg/day 
Age (years) 60 ± 12 59 ± 12 61 ± 13 
Gender Male 143 (67.5) 66 (62.3) 77 (72.6) 
 Female 69 (32.5) 40 (37.7) 29 (27.4) 
Body mass index (kg/m2) 30.5 ± 7.6 30.5 ± 7.4 30.4 ± 7.8 
 Normal weight (< 25.0) 49 (23.1) 24 (22.6) 25 (23.6) 
 Overweight (25.0 to 29.9) 60 (28.3) 26 (24.5) 34 (32.1) 
 Obese ( ≥ 30.0) 103 (48.6) 56 (52.8) 47 (44.3) 
NYHA 
functional 
class 
I 15 (  7.1) 4 (  3.8) 11 (10.4) 
II 81 (38.2) 40 (37.7) 41 (38.7) 
III 87 (41.0) 48 (45.3) 39 (36.8) 
IV 29 (13.7) 14 (13.2) 15 (14.2) 
Heart 
failure 
etiology 
Non-ischemic heart disease 122 (57.5) 64 (60.4) 58 (54.7) 
Ischemic heart disease 90 (42.5) 42 (39.6) 48 (45.3) 
Medication ACE inhibitors 143 (67.5) 71 (67.0) 72 (67.9) 
 ARB II* 39 (18.4) 14 (13.5) 25 (23.8) 
 Digoxin 62 (29.2) 30 (28.8) 32 (30.2) 
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 β blocker 185 (87.3) 95 (89.6) 90 (84.9) 
 Diuretics 163 (76.9) 78 (74.3) 85 (81.0) 
 Aldosterone antagonist 45 (21.2) 25 (23.8) 20 (18.9) 
Left ventricular ejection fraction (%) 33.9 ± 14.0 34.0 ± 14.9 33.8 ± 13.2 
 < 40% 136 (64.2) 66 (62.3) 70 (66.0) 
Total comorbidity score 3.0 ± 2.0 3.0 ± 1.9 3.0 ± 2.1 
 Hypertension 147 (69.3) 77 (73.3) 70 (67.3) 
 Diabetes mellitus 80 (37.7) 41 (38.7) 39 (36.8) 
Sodium (mg/day)* 3256 ± 1193 3029 ± 1087 3483 ± 1254 
 Less than 3,000 mg/day 109 (51.4) 60 (56.6) 49 (46.2) 
 Greater than 3,000 mg/day 103 (48.6) 46 (43.4) 57 (53.8) 
Figure Legend:  ACE= angiotensin converting enzyme; ARB II= Angiotension II receptor blocker; 
NYHA= New York Heart Association;  * p < 0.05 in the independent t-test  
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Figure 1A and1B. Difference in time to event between 2 groups with higher and lower lycopene 
intake stratified by sodium intake 
Survival curves were adjusted for age, gender, HF etiology, BMI, LVEF, NYHA class, and total 
comorbidity score after stratifying by sodium intake. 
Figure 1A 
 
Figure 1B 
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Table 4-1: Patient Characteristics 
Characteristics N (%) or Mean ± SD 
 
Total 
(n = 40) 
Intervention 
(n= 22) 
Control 
(n= 18) 
P value 
 
Age (years) 65 ± 9 65 ± 11 65 ± 9 .999 
Gender Male 23 8 (35) 15(65) .131 
 Female 17 10 (59) 7 (41)  
Body mass index (kg/m2) 31 ± 8 30 ± 5 32 ± 9 .257 
NYHA class II 28 (70) 16 (57) 12 (43) .677 
III 12(30) 6 (50) 6 (50)  
Heart failure 
etiology 
Non-ischemic  6 (15) 5 (83) 1 (17) .130 
Ischemic  40 (85) 17(50) 17 (50)  
Medication ACE inhibitors 35 (88) 16 (46) 19 (54) .987 
 β blocker 30 (75) 17 (57) 13 (43)  
 Diuretics 19 (48) 9 (47) 10 (53)  
Smoking History Current 8 (20) 4(50) 4(50) .935 
 Former 20 (50) 11(55) 9 (45)  
 Never 12/40 (30) 6 (50) 6 (50)  
Exercise frequency < 1 hour/week 21/40 (53) 11(52) 10 (48) .726 
> 1 hour/ week 19/40 (47) 11 (58) 8 (42)  
BNP Levels, pg/ml Baseline 167 ± 198 196 ± 237 132 ± 133 .316 
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Table 4-2: Serum C-reactive Protein and Uric Acid Pre- and Post-Intervention Compared 
Between the Groups Using B-type Natriuretic Peptide as a Covariate 
 
 C-reactive Protein mg/L* Uric Acid mg/dl* 
Intervention Control Intervention Control 
Baseline 3.4 ± 3.1 4.8 ± 3.4 7.2 ± 1.5 7.2 ± 2.3 
Post-Intervention  3.1 ± 2.8 4.5 ± 3.8 7.2 ± 1.3 7.3 ± 2.5 
Legend: Post-intervention was 30 days after baseline; *p > 0.05 for time and group effect 
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Table 4-3: Sodium and Lycopene Levels by Dietary Intake 
 
Legend: Sodium = mg/day; Lycopene = mcg/day; Post-intervention was 30 days after baseline; 
*p > 0.05 for time and group effect  
 Sodium intake* Lycopene intake 
Total Intervention Control Total* Intervention Control 
Baseline 2671 ±  
1252 
2858 ±1389 2443 ± 
1055 
9310 ± 
12849 
10543 ± 
14174 
7802 ± 
11235 
Post-
Intervention  
2864 ± 
1036 
3182 ±1063 2474 ± 879 14775 ± 
11926 
23317 ± 8332 4336 ± 
5545 
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Figure 4-1: C-reactive Protein Levels Pre- and Post-Intervention Compared Between Groups by 
Gender 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure Legend- F= Female; M= Male 
p = 0.024 for the  
interaction of group and gender  
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Figure 4-2: Uric Acid Levels Pre- and Post-Intervention Compared Between Groups by Gender  
  
Figure Legend- F= Female; M= Male 
p = 0.284 for the  
interaction of group and gender  
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Figure 4-3: Plasma Lycopene Compared Across Time Between the Groups 
 
 
 
 
 
 
 
 
 
 
 
Figure Legend- Plasma lycopene = mmol/L; Pre = Baseline measurement; Post = after 
intervention for 30 days 
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Figure 4-4: Pathway of Inflammation and Oxidative Stress in Patients with Heart Failure 
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